With treatment and close laboratory observation, pregnancy outcomes are improved, and adverse outcomes are decreased.

Many pregnant women experience remission of Grave disease towards the end of pregnancy due to the immunosuppressive effects of pregnancy and associated decrease in TRAb titers.

There is an increased risk of exacerbation or relapse in the 3 to 18 months after delivery due to the rebounding immune system, with the highest risk seven to nine months postpartum.